GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Shin Nippon Biomedical Laboratories Ltd (FRA:YB3) » Definitions » Gross-Profit-to-Asset %

Shin Nippon Biomedical Laboratories (FRA:YB3) Gross-Profit-to-Asset % : 18.25% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Shin Nippon Biomedical Laboratories Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Shin Nippon Biomedical Laboratories's annualized Gross Profit for the quarter that ended in Dec. 2023 was €81.1 Mil. Shin Nippon Biomedical Laboratories's average Total Assets over the quarter that ended in Dec. 2023 was €444.5 Mil. Therefore, Shin Nippon Biomedical Laboratories's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 18.25%.


Shin Nippon Biomedical Laboratories Gross-Profit-to-Asset % Historical Data

The historical data trend for Shin Nippon Biomedical Laboratories's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shin Nippon Biomedical Laboratories Gross-Profit-to-Asset % Chart

Shin Nippon Biomedical Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.84 19.03 25.29 26.01 20.20

Shin Nippon Biomedical Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.34 20.63 18.99 18.25 25.25

Competitive Comparison of Shin Nippon Biomedical Laboratories's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shin Nippon Biomedical Laboratories's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's Gross-Profit-to-Asset % falls into.



Shin Nippon Biomedical Laboratories Gross-Profit-to-Asset % Calculation

Shin Nippon Biomedical Laboratories's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=87.706/( (399.989+468.554)/ 2 )
=87.706/434.2715
=20.20 %

Shin Nippon Biomedical Laboratories's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=81.112/( (434.503+454.557)/ 2 )
=81.112/444.53
=18.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Shin Nippon Biomedical Laboratories Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Shin Nippon Biomedical Laboratories's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shin Nippon Biomedical Laboratories (FRA:YB3) Business Description

Traded in Other Exchanges
Address
8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.

Shin Nippon Biomedical Laboratories (FRA:YB3) Headlines

No Headlines